In The News

    • JUL 14 2017

    Musella Foundation Awards Oncoceutics New Research Grant

    The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma

    • JUN 09 2017

    ONC201 Results in Glioblastoma Featured in Bioscience Technology

    The recently published results from a clinical trial of ONC201 in patients with recurrent glioblastoma were featured in a recent article from Bioscience Technology. The full article can be read here.